Expanding v reserving exclusivity for drugs debated at US hearing
This article was originally published in SRA
Executive Summary
The 5,000-plus drugs under development in the US are evidence the current system for driving innovation is successful, and therefore, incentives like additional exclusivity protection should be reserved for true advances, an 11 June House of Representatives hearing was told.